AMRN Q2 2023 Earnings — Amarin Corporation plc Revenue & Financial Results | Market Cap Arena

AMRNAmarin Corporation plc

$310M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80M-15.1% YoY

Gross Profit

$43M53.2% margin

Operating Income

-$24M-29.9% margin

Net Income

-$18M-21.9% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

-6.8%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$860M

Total Liabilities

$291M

Stockholders' Equity

$569M

Cash & Equivalents

$233M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$94M	-15.1%
Gross Profit	$43M	$44M	-2.2%
Operating Income	-$24M	-$63M	+61.9%
Net Income	-$18M	-$70M	+74.9%

Revenue Segments

Product

$65M81%

Licensing And Royalty

$15M19%